Родники, ул. Советская, 10, каб. 3

+79109982962

luda3721@mail.ru

yab37

Главная

Услуги и цены

Новости

Контакты

Why Biogen’s medication, aducanumab, should get studied through an important part of the Affordable Care Act, the Patient Centers Outcomes Research Institute.


      That Wildly Expensive New Alzheimer’s Drug Needs Serious Testing

Getty Images/iStockphoto

The FDA’s controversial approval of aducanumab for Alzheimer’s Disease will cost taxpayers dearly, even though there’s no evidence it will benefit patients and caregivers. Stock analysts estimate Biogen’s take from the drug, which it priced at $56,000 a year, could reach $40 billion annually, most of which will automatically get paid by Medicare.
Source